Measurement of in Vivo Mitochondrial Capacity in Infants

Measurement of in Vivo Mitochondrial Capacity in Infants: a 31P-MRS Pilot Study

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03976596

Enrollment

Registered

2019-06-06

Start date

2019-05-21

Completion date

2019-07-02

Last updated

2026-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Infants

Keywords

neonates, mitochondria, MRI

Brief summary

The overarching aim of this project is to determine the test re-test reliability of 31P-magnetic resonance spectroscopy measurements in infants. Primary endpoints include two separate measures of in vivo mitochondrial capacity (ATPmax) over a 1-10 day period to assess feasibility and reliability.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

14 Days to 28 Days

Healthy volunteers

Yes

Inclusion criteria

* healthy, full-term infant * aged 14-28 days at Visit 1 * willingness of parents to be notified of incidental findings from study procedures

Exclusion criteria

* born preterm * implanted metal or electronic objects that render MRI unsafe * unable to complete 2 clinic visits 1-10 days apart at Pennington Biomedical Research Center

Design outcomes

Primary

Measure	Time frame	Description
In vivo mitochondrial capacity (ATPmax)	1 day	In vivo mitochondrial capacity as measured by phosphorus magnetic resonance spectroscopy

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLeanne M Redman, PhD

Pennington Biomedical Research Center

Outcome results